MARKET

GNPX

GNPX

Genprex Inc
NASDAQ
0.2819
+0.0059
+2.14%
After Hours: 0.2870 +0.0051 +1.81% 19:08 05/13 EDT
OPEN
0.2801
PREV CLOSE
0.2760
HIGH
0.2871
LOW
0.2692
VOLUME
661.05K
TURNOVER
--
52 WEEK HIGH
4.090
52 WEEK LOW
0.2200
MARKET CAP
6.81M
P/E (TTM)
-0.0528
1D
5D
1M
3M
1Y
5Y
1D
Genprex Q1 EPS $(0.26) Beats $(0.41) Estimate
Benzinga · 1d ago
Weekly Report: what happened at GNPX last week (0505-0509)?
Weekly Report · 1d ago
Genprex Inc <GNPX.OQ> expected to post a loss of 41 cents a share - Earnings Preview
Reuters · 3d ago
Genprex Announces Research Agreement for Diabetes Therapy
TipRanks · 6d ago
Genprex Enters Sponsored Research Agreement With The University Of Pittsburgh To Study Diabetes Gene Therapy In Type 1 And Type 2 Diabetes
Benzinga · 6d ago
GENPREX SIGNS SPONSORED RESEARCH AGREEMENT WITH THE UNIVERSITY OF PITTSBURGH TO STUDY DIABETES GENE THERAPY IN TYPE 1 AND TYPE 2 DIABETES
Reuters · 6d ago
Genprex Secures Exclusive Patent License for Reqorsa
TipRanks · 05/06 11:51
Genprex Enters Exclusive Patent License To Additional Gene Therapy Technology With UTHealth Houston For The Treatment Of Glioblastoma
Benzinga · 05/06 11:09
More
About GNPX
More
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles. The Company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Using a different gene therapy delivery system, the Company is also developing its preclinical diabetes candidate GPX-002 using the same construct for both Type 1 diabetes and Type 2 diabetes. It conducts preclinical research to explore how REQORSA may be administered in other solid tumors.
Recently
Symbol
Price
%Change

Webull offers Genprex Inc stock information, including NASDAQ: GNPX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNPX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GNPX stock methods without spending real money on the virtual paper trading platform.